 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Dr. Hermann began practice in Marietta in 1984 on completion of his fellowship training at Emory University. A few years later he merged his practice with another forming NGOC. Dr. Hermann is actively engaged in clinical trials and research, currently serving as Medical Director of the Wellstar Cancer Program. He is Board Certified in Internal Medicine and Medical Oncology and sees patients at the Marietta Center. |
| ROBERT C. HERMANN, M.D. | |
| OFFICE ADDRESS | NORTHWEST GEORGIA ONCOLOGY CENTERS, P.C. MARIETTA CENTER 340 Kennestone Hospital Blvd., Suite 200 William S. Gibbons Cancer Research Institute Marietta, GA 30060 Phone: (770) 281-5100 Fax: (678) 581-7105 Email: rhermann@ngoc.com |
| PERSONAL DATA | Birthplace: Wilmington, DE |
| UNDERGRADUATE EDUCATION | BA, Diversified Major in Biology and Psychology, June, 1973 Southwestern at Memphis, TN |
| MEDICAL EDUCATION | Doctor of Medicine University of Tennessee College of Medicine Memphis, TN June, 1979 |
| POSTDOCTORAL TRAINING | INTERNSHIP and RESIDENCY Internal Medicine Medical College of Virginia Richmond, VA, July 1979 – June 1982 FELLOWSHIP Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA, July, 1982 – June, 1984 |
| BOARD CERTIFICATION | Diplomate, National Board of Medical Examiners, July, 1980 Diplomate, American Board of Internal Medicine, September, 1982 Diplomate, Sub-specialty Medical Oncology, American Board of Internal Medicine, November, 1985 |
| MEDICAL LICENSURE | State of Georgia, 1982 (Active) |
| PROFESSIONAL SOCIETIES | Alpha Omega Alpha, 1979 -Present American College of Physicians-American Society of Internal Medicine, 1984 -Present Cobb County Medical Society, 1984 - Present Medical Association of Georgia, 1984 - Present American Society of Clinical Oncology, 1985 - Present Charter Member and Director, Georgia Society of Clinical Oncology, 1985 - Present American Medical Association, 1996 – Present American College of Physician Executives, 1998-Present Southern Association for Oncology, 1998-Present Southern Medical Association, 1998-Present |
| HONORS | Recipient of Scholastic Achievement Award, 1979 Election to Alpha Omega Alpha, Beta Chapter of Tennessee, 1979 |
| CLINICAL RESEARCH AFFILIATIONS | Investigator, National Cancer Institute, 1984-present Associate Principal Investigator, Atlanta Regional CCOP, 1991-1995 Investigator, Atlanta Regional CCOP, 1991-Present Investigator, National Surgical Breast and Bowel Project (NSABP) Oct 1991- present Investigator, Southwest Oncology Group (SWOG), Nov 1991- present Investigator, Minnie Pearl Cancer Research Network (MPRN), 1995-present Investigator, American Medical Research Institute, 1999-2000 Investigator, WellStar Health System Cancer Research Program, 1991-present Principal Investigator and Medical Director, WellStar Cancer Program, July 1998- present. Investigator, Georgia Oncology Partners Research and Education Foundation, 2001-2005. Investigator, North Central Cancer Treatment Group, May 2003- present. Investigator, Translational Oncology Research International, June 2004-present Investigator, Accelerated Community Oncology Research Network, 2004-present |
| PUBLICATIONS | ARTICLES Carcinoma of Unknown Primary Site: Phase II trials with docetaxel plus cisplatin or carboplatin, F.A. Greco, J.B. Erland, L.H. Morrissey, H.A. Burris III, R.C. Hermann, R. Steis, D Thompson, J. Gray, and J.D. Hainsworth. Annals of Oncology 11: 211-215, 2000. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. The American Society of Clinical Oncology Bisphosphonates Expert Panel, J Clin Oncol 18: 1378-1391, 2000. Single-agent Rituximab as First-line and Maintenance Treatment for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: a Phase II Trial of the Minnie Pearl Cancer Research Network., Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network. J Clin Oncol. 2003 May 1;21(9):1746-51. ABSTRACTS A Study of UFT + Leucovorin (L) Given as a Twice Daily (BID) Regimen in the Treatment of Patients (PTS) with Metastatic Breast Cancer (MBC). Gabriel N. Hortobagyi, N Ibrahim, R. Young, M Karwal, J Murray, M Cristofanilli, R Hermann, M D. ASCO Proceedings, 2001, Abstract 186 Rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial, J. D. Hainsworth, S. Litchy, J. H. Barton, G. A. Houston, R. C. Hermann, J. E. Bradof, F. A. Greco, ASCO Proceedings, 2003, Abstract 2332. |
| MAJOR RESEARCH INTERESTS |
Clinical Trials (Oncology & Hematology) For a listing of the Active Clinical Trials that NGOC participates in, click here Use your browser's "back" button to return to this physician's page |
